Fabio Gelsomino - Concepedia

Author

Fabio Gelsomino

University of Modena and Reggio Emilia ORCID

Also Known As

F Gelsomino, F. Gelsomino, Fabio Gelsomino, Gelsomino F, Gelsomino, Fabio, Gelsomino,Fabio, Loschi Pietro

153

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

University of Modena and Reggio Emilia Istituti di Ricovero e Cura a Carattere Scientifico Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Sapienza University of Rome Azienda Ospedaliera Sant'Andrea

About

Fabio Gelsomino is an author at University of Modena and Reggio Emilia specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	2.5K
2	Health Sciences	4	4	182
3	Public Health	1	1	13
4	Biostatistics	1	1	13
5	Hepatology	1	1	13

Fabio Gelsomino

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsImmunotherapyTumor Immunity	2018	2K
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 Thierry André, Sara Lonardi, Ka Yeung Mark Wong, Annals of Oncology	2022	234
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer Alessandro Passardi, Emanuela Scarpi, Luigi Cavanna, Oncotarget	2016	152
Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization Marta Schirripa, Paola Biason, Sara Lonardi, Clinical Cancer Research	2019	104
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors Francesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, Neuroendocrinology	2016	91
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study Davide Campana, Thomas Walter, Sara Pusceddu, Endocrine Neuroendocrine NeoplasmsEpigenetic RegulationMgmt Promoter MethylationMedicineEpigenetic Change	2017	75
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer Joris van de Haar, Xuhui Ma, Salo Ooft, Nature Medicine	2023	74
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix Nicole Brighi, Stefano La Rosa, Giulio Rossi, Annals of Surgery	2018	68
Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. Thierry André, Sara Lonardi, Mark Wong, Journal of Clinical Oncology Dmmr/msi-h McrcImmunodeficienciesImmunologyPathologyPharmacotherapy	2018	66
Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. Michael J. Overman, Francesca Bergamo, Ray McDermott, Journal of Clinical Oncology Dmmr/msi-h McrcCancer ManagementPathologyLong-term SurvivalPharmacotherapy	2018	61

Page 1